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Objectives: Germline genome sequencing (GS) is becoming mainstream in cancer diagnosis and risk
management. Identifying knowledge gaps and determinants of health behavior change intentions will
enable effective targeting of educational and management strategies to translate genomic findings into
improved cancer outcomes.
Methods: Probands diagnosed with cancer of likely genetic origin that consented to but not yet undergone
GS, and their biological relatives, completed a cross-sectional questionnaire assessing GS knowledge and
hypothetical intention to change behaviors.
Results: Probands (n = 348; 57% university educated) and relatives (n = 213; 38% university educated) had
moderate GS knowledge levels, with greater knowledge associated with higher education. Both populations
reported high behavioral change intentions, significantly associated with being female (p = 0.01) and greater
perceived importance of GS (p < 0.001), and for probands: being from English-speaking households
(p = 0.003), higher socio-economic status (p = 0.01) and greater self-efficacy (p = 0.02).
Conclusions: Increasing GS knowledge will enable realistic participant expectations surrounding germline
GS. Actual behavior change should be monitored to determine whether increased cancer risk knowledge
results in altered cancer-related behavior and ultimately, cancer outcomes.
Practice implications: Educational resources should target specific populations to ensure informed decisionmaking and expectation management. Support tools facilitating and maintaining behavioral change may be
needed to achieve improved cancer patient outcomes.
© 2021 Published by Elsevier B.V.
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1. Introduction
Genome sequencing (GS) is increasingly being used to identify
hereditary genetic drivers of disease, and to inform clinical
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management [1]. In cancer, germline genetic testing has focused on
single gene testing or small gene panels associated with specific
cancer types, exemplified by BRCA1/2 in breast cancer patients and
mismatch repair genes in colorectal cancer patients [2,3]. Sequen
cing technology cost has significantly declined, making GS more
accessible. Consequently, germline and somatic tumor GS have ex
panded to include hundreds of genes to guide cancer treatment,
prognosis and risk management including prevention and surveil
lance [4,5]. However, the amount and complexity of genomic
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Furthermore, most studies have measured intent to, rather than
actual, change following receipt of genomic results, reflecting the
difficulty and greater cost of longitudinal studies. The intentionbehavior gap (the failure to translate intentions into action) is well
documented; data suggest that intention predicts a mere 30–40% of
variation in health behavior [26]. However, knowledge of the de
terminants and strategies that facilitate translation of intention to
behavior is increasing [27].
Few of the above studies were informed by theory. Protection
Motivation Theory (PMT) postulates that individuals shield them
selves from threats based on the perceived efficacy of preventive
behavior and self-efficacy of performing the preventive behavior
[28]. Accordingly, individuals’ perception of the degree of personal
threat posed by cancer, GS knowledge, and perceptions of the effi
cacy of GS in guiding preventive management, and self-efficacy for
undertaking preventive behaviors, will impact their intentions to
undertake such behaviors.
Notably, a negative attitude toward uncertainty has been found
to increase threat appraisal [29]. Furthermore, Brouwers and Sor
rentino showed that attitude toward uncertainty provides greater
predictive power when combined with PMT, to explain individuals’
responses to increasing threat [30]. The authors argue that people
with a negative attitude toward uncertainty are more motivated to
see information and ways to resolve uncertainty, particularly under
conditions of increasing threat. Yet these variables have rarely been
explored in relation to intention to undertake preventive behaviors
following GS.
The current study aimed to address gaps in the literature iden
tified above by investigating baseline knowledge and determinants
of behavioral change intention in patients undergoing germline GS.
Our goal was to help health professionals to more effectively target
future educational and management strategies that will translate
genomic findings into improved health outcomes.
The Genetic Cancer Risk in the Young (RisC) study is a cohort
study of participants with a personal history of cancer, investigating
heritable cancer causes and future cancer risk using germline GS. A
psychosocial substudy of RisC (Psychosocial Issues in Genomic
Oncology - PiGeOn) [31] is exploring psychosocial and behavioral
outcomes in RisC participants. Using baseline quantitative data from
the PiGeOn study, the study hypothesis was that:
Controlling for demographic and cancer-related variables that
may impact the outcomes, PMT variables (greater perceived cancer
susceptibility, perceived importance of GS, and self-efficacy); higher
levels of satisfaction with the decision to have GS (as a result of more
realistic expectations of GS); and more negative attitudes toward
uncertainty would be associated with greater GS knowledge and
behavioral intentions.

information provided by more extensive testing makes it difficult to
fully understand.
As GS becomes mainstream, it is important to assess patients’
knowledge of germline GS, and whether they intend to act on re
sults. Adequate knowledge about the benefits and limitations of GS
ensures that patients have realistic expectations, as demonstrated by
a previous study showing that patients undergoing genetic coun
selling that utilized a website providing cancer-specific information
had less unrealistic expectations about genetic testing [6]. Knowl
edge of germline GS may also provide patients with greater con
fidence in their ability to cope with receiving test results, temper
disappointment, lessen anxiety/distress and support decisionmaking [7,8]. Finally, expansive GS will only yield expected benefits
if participants use results to guide risk reduction, early detection and
cancer prevention behaviors [9].
Genomic knowledge varies considerably, depending on the pa
tient population and method of knowledge assessment, patients’
level of education and previous attendance at a family cancer clinic
(FCC) [8,10,11]. Participants in previous studies included those who
are healthy seeking disease risk information, and those with rare
disorders undergoing GS to guide treatment. A recent systematic
review of knowledge of genomics in cancer patient populations re
vealed limited knowledge and high need for education [12]. This
concurs with the broader literature on genetics, where key issues are
often poorly understood by patients [13–15].
Factors associated with poorer knowledge included rural re
sidence, older age, minority status, and lower education, as well as
low numeracy and literacy [16]. Few studies have examined psy
chological factors associated with knowledge of genomics. Health
behavior models suggest that those with high perceived suscept
ibility to disease are more likely to act to prevent that disease, and
that the decision to act is reached through a deliberate reasoning
process or analysis of susceptibility, potential actions, potential
costs, and anticipated outcomes [17]. Thus, those with higher per
ceived susceptibility may be more motivated to seek out and un
derstand information to support this decision-making.
One study examined associations between self-efficacy, per
ceived susceptibility, attitude toward uncertainty and satisfaction
with the decision to have testing, and knowledge of tumor mutation
profiling in advanced cancer patients [18]. The authors found a sig
nificant association only for satisfaction with decision. However,
how these results generalize to patients affected by rare and less
common cancers undergoing GS to determine future cancer risk is
unknown.
Overall, the evidence that genomic information will influence
behavior is lacking [19]. Most studies of lower-risk genotypes have
evaluated genetic feedback based on single-gene variants, revealing
little behavioral impact, either positive or negative [20]. A systematic
review and meta-analysis of trials delivering personalized DNAbased estimates of disease risk to the general public for single
conditions where risk could be reduced by behavior change, found
no evidence of impacts on diverse behaviors such as smoking ces
sation, diet or physical activity, although the authors noted the
overall poor quality of studies [21].
Receiving genomic results has, however, been shown to en
courage more frequent health screening, altered lifestyle behaviors
and other preventative strategies in healthy adults [22], if the results
are linked to known effective prevention strategies [23,24] and if the
risks are high. For example, participants in one study were more
motivated to limit sun exposure and increase screening after they
received melanoma risk information based on family history and
genetic results (CDKN2A mutation positive) versus family history
alone [25]. However, the extent to which these results generalize to a
population who have already experienced cancer, is unknown. Be
havioral outcomes of risk feedback based on testing for numerous
gene variants simultaneously remain largely unexplored.

2. Methods
2.1. Participants and study design
Participants were recruited from the RisC study, which recruits
adults with a likely genetic predisposition to cancer: a cancer diag
nosis between 16 and 40 years of age, or two cancer diagnoses at <
50 years of age, or three separate cancer diagnoses at any age
(probands). RisC participants are recruited by clinical cancer ge
neticists, genetic counselors and oncologists, or self-referral. While
gaining consent, a researcher provides participants with written
information about germline GS and the study, offered participants
the opportunity to ask questions and gives contact information for
study personnel if questions arose in due course. Participants pro
vide a blood sample from which DNA is extracted and germline GS
performed. If pathogenic variant(s) are found in the current clinically
actionable American College of Medical Genetics reportable gene
list, participants are referred to a familial cancer clinic or other
2

C.E. Napier, G. Davies, P.N. Butow et al.

Patient Education and Counseling xxx (xxxx) xxx–xxx

appropriate clinical service and offered tailored risk management
plans. Biological relatives, often parents, are also invited to enroll in
the RisC study. Participants receive GS results approximately 18
months after consent.
When consenting to the RisC study, participants also consent to
the PiGeOn psychosocial study [31]. PiGeOn participants complete
three questionnaires, administered at consent (baseline), and three
months and one year after consent. Participants are reminded by
phone and/or email if questionnaires are not received within three
weeks of sending. The current paper reports baseline quantitative
results examining demographic, disease and psychological pre
dictors of GS knowledge and intended behavioral change at baseline.
All participants in the RisC study provided written, informed
consent. Human ethics approval was obtained from Human Research
Ethics Committees at St Vincent’s Hospital, Sydney, Australia (HREC/
16/SVH/24).

quartiles; the lowest quartile was categorized as ‘low’, the middle
two quartiles as ‘moderate’, and the upper quartile as ‘high’.
2.2.4. Behavioral intentions
Participants completed a study-developed measure based on the
literature, assessing intention to change six behaviors (diet, exercise,
alcohol consumption information seeking, health screening and
stress management) if they had a known gene variant that increased
their cancer risk (Appendix A). Items were rated on a 5-point Likert
scale from ‘Strongly disagree’ (1) to ‘Strongly agree’ (5) and averaged
(Cronbach’s alpha 0.89). Higher scores indicate greater intention to
change behavior. Average scores above 4.0 were labeled as ‘high’.
2.2.5. Perceived importance of GS
Five items asked participants to rate importance of GS, with
higher scores corresponding to greater perceived importance
(Cronbach’s alpha 0.58) [33].

2.2. Measures
2.2.6. Self-efficacy
Self-efficacy was assessed using four study-adapted questions
based on those developed by Rosenberg and colleagues [34]. Ques
tions included whether participants felt they would be able to cope
with various gene variant outcomes and telling family members
about potentially inherited gene variants. Greater scores indicated
greater ability to cope with gene variant outcomes (Cronbach’s
alpha 0.88).

Probands and their relatives completed an identical ques
tionnaire, including validated scales where available and purposedesigned questions as appropriate.
2.2.1. Demographic variables
Participant demographics included: gender, age, education, oc
cupation, language spoken at home used as a determinant of a cul
turally and linguistically diverse background, postcode (for
socioeconomic status [SES] and remoteness [Accessibility and
Remoteness Index of Australia]), and marital and parental status. An
occupation was designated a medical/science occupation if the
education toward or the occupation itself involved scientific learning
or evidence-based medical practice (e.g. research scientists, regis
tered medical practitioners, allied health professionals).
Classifications were made by one member of the research team and
cross-checked by another.

2.2.7. Perceived susceptibility
A validated scale [35], comprising a 5-point Likert scale ranging
from ‘Much lower’ (0) to ‘Much higher’ (4), was used to assess par
ticipants’ perceived susceptibility of a) having another cancer diag
nosis/developing cancer and b) having a gene variant linked to
cancer risk, compared to an average person of the same age and
gender as them. Participants also rated their perceived susceptibility
of having another cancer diagnosis/developing cancer on a visual
analogue scale ranging from 0–100%. Scores were normalized and
averaged; higher scores indicate greater perceived susceptibility
(Cronbach’s alpha 0.78).

2.2.2. Cancer variables
Personal and family history of cancer, previous attendance at an
FCC, time since (first) cancer diagnosis, and cancer type(s) were
collected.
Demographic and cancer variables were assessed to ensure
variables that might impact knowledge and behavioral intention
(such as greater exposure to information and resources in an urban
center, and through education) were controlled for in the analysis.

2.2.8. Attitude toward uncertainty
The seven-item scale from Braithwaite and colleagues was used
to assess participants’ desire for certainty regarding medical tests
[36], where higher scores indicate a greater desire for certainty.
2.2.9. Satisfaction with decision
The scale was used to assess how satisfied participants were with
their decision to undergo GS [37]; higher scores indicate higher
decisional satisfaction.

2.2.3. Knowledge of genomics
We developed a seven-item study-specific knowledge scale
(questions listed in Fig. 3). The only validated knowledge scale re
levant to GS published at the time of study inception [32] was va
lidated on ClinSeq participants who had consented to undergo GS as
part of a long term research study. As a knowledge scale relevant to
the benefits and limitations of GS for cancer risk was not available, a
study-specific scale was developed. A multi-disciplinary advisory
group comprising geneticists, genetic counsellors, genomic scientists
and psycho-oncologists nominated issues they felt were critical for
participants to understand to have realistic expectations of test
outcomes. Items addressed aspects such as the likelihood of ob
taining informative results, cancers in which informative results are
more likely to be found, and availability of tailored risk-management
or treatment options. Items were multiple choice and included a
‘Don’t know’ option. Following a pilot with ten participants, slight
modifications to wording were made to increase the clarity of items.
Further piloting with another ten participants confirmed the scale
had face validity and was understandable. A total score (0–100%) was
calculated from the number of correct responses, with ‘Don’t know’
responses scored as incorrect. Knowledge scores were divided into

2.3. Analyses
Descriptive statistics were used to summarize the data. IBM SPSS
Statistics (version 25) was used for data analyses. A multiple linear
regression analysis was conducted with GS knowledge score as the
outcome variable, and an ordinal regression was conducted with
average behavioral intention scores as the outcome variable.
Education was treated as an interval variable, so the regression
coefficient represents the mean change with each increase in edu
cation level (i.e. completed Year 11 or 12 versus vocational training).
Knowledge scores were normally distributed in both the probands
and relatives (D’Agostino and Pearson normality test).
As summary scores for behavioral intention were negatively
skewed, the scores were categorized into four ordered categories;
i) <3, ii) ≥3 and <4, iii) ≥4 and <5, and iv) 5. The predictor variables for
both regression analyses included the demographics listed above.
Perceived importance of GS, satisfaction with decision to have GS,
3
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Fig. 1. Flowchart detailing participants’ referral, consent and questionnaire completion in the RisC Study.

self-efficacy, perceived susceptibility and attitude to uncertainty
measures were included as predictors of GS knowledge, in line with
PMT. All variance inflation factors were below 10, indicating no
collinearity issues for these predictors. Missing data was handled in

the regression using complete case analysis, which resulted in
sample sizes for the regressions presented in Tables 2 and 3 of 301
and 190 for probands and relatives, respectively. This corresponds to
86% and 89% of the full cohort respectively.

Fig. 2. Primary cancer sites of probands. Number of instances of each cancer type is indicated. Total number of cancers in 348 probands is 515 due to participants having multiple
primary cancers. Benign conn. tissue tum.: Benign connective tissue tumors.
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Correct

Incorrect

Don't know

Missing

If one of your parents has a gene variant, the
chance of inheriting that gene variant is:50%

Probands

Whole genome sequencing
involves testing: 20,000 genes

Probands

If 100 patients have whole genome sequencing,
in how many people will a genetic fault be found
that can manage risk?:1-10 (version 1)

Probands

The results of whole genome sequencing are
helpful for making decisions about future cancer
risks: Sometimes (version 2)

Probands

At the moment, we know most about genetic
faults that can guide prevention in breast and
colorectal cancers: Yes (version 1)

Probands

Whole genome sequencing is helpful for
understanding the risk of:Some types
of cancer (version 2)

Probands

The likelihood of finding a gene variant to guide
prevention depends on the type of cancer. True

Probands

Sometimes we find a gene variant
we know nothing about: True

Probands

Relatives

Relatives

Relatives

Relatives

Relatives

Relatives

Relatives

Relatives

Sometimes cancer treatment, screening or
preventative surgery can be offered to people
with a disease-causing gene variant. The costs
of this would be: Covered in full by Medicare
or Only available through a clinical trial

0

Probands
Relatives

25

50
Percent of cohort

75

100

Fig. 3. Study-developed genome sequencing knowledge questions. Correct answers to each item are indicated in bold and italics. Two questions were changed between versions 1
and 2 of the questionnaire. N = 348 for probands and N = 213 for relatives, except version 1 questions (N = 144 for probands and N = 60 for relatives) and version 2 questions
(N = 204 for probands and N = 153 for relatives).

3. Results

3.2. Knowledge of GS

3.1. Cohort description

Probands and relatives had similar knowledge scores at baseline
(mean = 45% and 43%, respectively). Three-quarters of both probands
and relatives correctly answered the question “Sometimes we find a
gene variant we know nothing about”, and approximately half of
probands and relatives correctly identified the number of genes in
the genome, likelihood of transmission of a genetic variant, and that
clinical utility of genetic risk of cancer depends on the cancer type
(Fig. 3). However, 90% of probands and 95% of relatives either did not
know or gave an incorrect answer to the question “If 100 patients
have whole genome sequencing, in how many people will a genetic fault
be found, that can manage risk” (answer: 1–10 people), and over twothirds of probands and relatives did not know that GS was only
sometimes helpful for making decisions about future cancer risks.
Univariate results suggested a difference in knowledge between

Between August 2016 and August 2019, 379 probands and 231
biological relatives were consented to the RisC study. Survey com
pletion rates were 348/379 (92%) and 213/231 (92%) for probands
and relatives, respectively (Fig. 1). Relatives consisted mostly of
parents (207/213), with the remaining six participants being chil
dren or siblings of the proband. Descriptive statistics of both pro
bands and relatives are reported in Table 1. Over 70% of the
participants had a rare or less common cancer, defined as cancers
with an incidence of < 6 or < 12/100,000 population, respectively.
Rare and less common cancer types included those arising from
bone and soft tissue (sarcomas), brain, pancreas, kidney, thyroid,
appendix and adrenal gland (Fig. 2).
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Table 1
Descriptive statistics.
Probands
(N = 348)
N, %
Demographics
Sex
Female
Male
Age (years)
Mean (SD)
Median (IQR)
Range
Education
Primary school
Year 7 or 8
Year 9 or 10
Year 11 or 12
Vocational Training
University did not graduate
University graduated
Missing
Medical/science occupation
Yes
Non-English-speaking
background
Yes
Socio-economic status
Mean (SD)
Range
Accessibility and Remoteness
Index of Australia
Urban
Marital status
Married
Biological children
Yes
Cancer history
Visited a family cancer clinic
Yes
Family history of cancer
Yes
Cancer diagnosis
Yes
Multiple primary cancers
Yes
Time since first cancer diagnosis
(years)
Mean (SD)
Median
Range
Cancer incidence
Common
Less common
Rare

Behaviors/attitudes
Knowledge
Mean (SD)
Range
Behavioral intentions
Mean (SD)
Range
Perceived importance
Mean (SD)
Range
Satisfaction with decision
Mean (SD)
Range
Attitude toward uncertainty
Mean (SD)
Range
Self-efficacy
Mean (SD)
Range
Perceived susceptibility

Relatives
(N = 213)
N, %
Mean (SD)
Range

230 (66%)
118 (34%)

126 (59%)
87 (41%)

41.82 (13.72)
39 (17)
16–83

63.13 (8.48)
64 (11)
31–87

0
2 (0.6%)
23 (7%)
40 (11%)
56 (16%)
29 (8%)
197 (57%)
1 (0.3%)

1 (0.5%)
11 (5%)
43 (20%)
19 (9%)
42 (20%)
13 (6%)
82 (38%)
2 (1%)

28 (8%)

16 (8%)

77 (22%)

22 (10%)

7.63 (2.56)
1-10

6.62 (2.83)
1-10

326 (94%)

180 (85%)

183 (53%)

163 (77%)

22 (10%)

287 (83%)

213 (100%)

348 (100%)

49 (23%)

45% (25%)
0–100%

43% (25%)
0–86%

4.26 (0.69)
1-5

4.21 (0.62)
1-5

3.77 (0.55)
1.40–5

3.75 (0.54)
2-5

4.34 (0.54)
1.33–5

4.26 (0.54)
3-5

4.02 (0.70)
1.57–5

3.84 (0.70)
1.43–5

4.13 (0.69)
1-5

4.14 (0.64)
2-5

47.09 (16.49)
0–100

3.3. Intention to change behavior
Overall, both probands and relatives indicated having strong in
tentions to change their behaviors (means = 4.26 and 4.21, respec
tively, out of a possible score of 5; Table 1). More than half of both
probands and relatives ‘Strongly agreed’ that they intended to seek
more information if a gene variant linked to cancer risk was iden
tified via GS. In contrast, only 35% and 28% of probands and relatives,
respectively, reported strong intentions (‘Strongly agree’) to change
the amount of alcohol consumed in response to learning they carried
a cancer-risk associated gene variant (Fig. 5).
Ordinal regression analyses revealed that gender and higher
perceived importance of GS were significant predictors of intention
to change behavior for both probands and relatives. Specifically, the
ordered odds of females having greater intention to change behavior
was 1.93 times (95% CI: 1.16–3.19, p = 0.011) for probands, and 2.29
times (95% CI: 1.19–4.38, p = 0.013) for relatives, compared to males
(Table 3). For each categorical increase in perceived importance of GS
(i.e. ‘Agree’ to ‘Strongly agree’), the ordered odds of having greater
intention to change behavior increased by 3.80-fold (95% CI:
2.43–5.94, p < 0.001) for probands and by 3.71-fold (95% CI:
2.00–6.89, p < 0.001) for relatives. Knowledge levels did not predict
intent to change behavior for either probands (95% CI: 0.26–1.92,
p = 0.490) or relatives (95% CI: 0.16–2.07, p = 0.391).
For probands, additional predictors of greater intention to change
behavior included: being from an English-speaking background,
higher SES, higher self-efficacy and having higher negative attitudes
towards uncertainty. The ordered odds of probands from an Englishspeaking background having greater intentions to change behavior
was 2.51 (95% CI: 0.98–1.12, p = 0.003) times that of participants
from a non-English-speaking background. For every one-unit

7.45 (9.28)
3.83
0–52.17

Relatives
(N = 213)
N, %

64.03 (18.09)
0–100

probands with secondary only vs vocational training or university
education (p = 0.05), and a highly significant difference in relatives
(p < 0.001) (Fig. 4).
A multiple linear regression revealed that higher levels of edu
cation, previous attendance at an FCC, and being married were sig
nificant predictors of probands’ GS knowledge scores (Table 2).
Predictors of GS knowledge scores for relatives included: a greater
level of education, a medical or science occupation, and greater selfefficacy. Every categorical increase in education level (i.e. completed
Year 11 or 12 compared to post-secondary education) led to
knowledge score increases of 2.5% for probands (95% CI: 0.40–4.59,
p = 0.020) and 2.8% for relatives (95% CI: 0.56–4.98, p = 0.015). Fur
thermore, probands who had previously visited an FCC or were
married, were predicted to have an 8% higher GS knowledge score
(FCC - 95% CI: 2.01–14.19, p = 0.009; married - 95% CI: 1.82–14.08,
p = 0.011).
Similarly, there was an 8% increase in relative’s GS knowledge
score for each categorical increase (i.e. ‘Agree’ to ‘Strongly agree’) in
relatives’ perceived self-efficacy to cope with results (95% CI:
2.27–14.39, p = 0.007). Relatives with a medical or science occupa
tion scored 16% higher with regard to their knowledge of GS com
pared to relatives without a medical or science occupation (95% CI:
3.43–29.10, p = 0.013), which was the greatest increase in GS
knowledge score predicted by any variable within either of the two
cohorts.

97 (28%)

100 (29%)
25 (7%)
223 (64%)
Probands
(N = 348)
N, %

Relatives
(N = 213)
N, %

SD: standard deviation; IQR: interquartile range

183 (53%)

91 (26%)

Probands
(N = 348)
N, %
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Table 2
Summary of regression analyses for variables predicting knowledge about GS.
Independent variables

Sex
Female (Ref. category: Male)
Age (for every 10 year increase)
Education
Medical/science occupation
Yes (Ref. category: No)
English-speaking background
Yes (Ref. category: No)
Socio-economic status
Accessibility and Remoteness Index of Australia
Urban (Ref. category: Remote)
Previous visit to a family cancer clinic
Yes (Ref. category: No)
Married
Yes (Ref. category: No)
Biological children
Yes (Ref. category: No)
Family history of cancer
Yes (Ref. category: No)
Cancer diagnosis
No (Ref. category: Yes)
Multiple primary cancers
Yes (Ref. category: No)
Time since diagnosis
Cancer incidence
Common
Less common
Rare
Behavioral intentions
Perceived importance
Satisfaction with decision
Self-efficacy
Perceived susceptibility (10 units scaled)
Attitude toward uncertainty

Probands

Relatives

Regression coefficient (95% CI)

p value

Regression coefficient (95% CI)

p value

4.66 (−1.25 to 0.11)
0.97 (−2.19 to 4.12)
2.49 (0.40–4.59)

0.121
0.547
0.020*

-0.09 (−7.60 to 7.41)
-1.26 (−5.85 to 3.34)
2.77 (0.56–4.98)

0.980
0.590
0.015*

6.88 (−2.55 to 16.32)

0.152

16.26 (3.43–29.10)

0.013*

4.42 (−2.45 to 11.30)
-0.03 (−1.17 to 1.10)

0.207
0.952

-0.95 (−12.96 to 11.06)
-0.02 (−1.37 to 1.38)

0.876
0.982

6.79 (−6.44 to 20.01)

0.313

3.04 (−9.98 to 16.06)

0.645

8.10 (2.01–14.19)

0.009**

6.81 (−4.58 to 18.21)

0.240

7.95 (1.82–14.08)

0.011*

-5.48 (−13.85 to 2.88)

0.197

-2.88 (−9.99 to 4.23)

0.427

6.91 (−1.05 to 14.86)

0.089
2.50 (−6.01 to 11.00)

0.563

-2.28 (−8.77 to 4.22)
-0.62 (−7.86 to 6.62)
0.51 (−8.10 to 9.09)
8.33 (2.27–14.39)
0.46 (−1.74 to 2.66)
-4.61 (−10.61 to 1.40)

0.490
0.866
0.906
0.007**
0.682
0.132

4.77 (−3.49 to 13.03)
-0.30 (−0.66 to 0.07)

0.257
0.116

-0.77 (−6.98 to 5.44)
4.58 (−5.48 to 14.64)
Ref. category
-3.72 (−8.22 to 0.78)
2.90 (−2.36 to 8.16)
1.63 (−5.13 to 8.40)
2.08 (−2.36 to 6.52)
-1.24 (−2.76 to 0.27)
-3.36 (−7.88 to 1.17)

0.808
0.371
0.104
0.279
0.635
0.357
0.107
0.145

Ref. = reference
*
p < 0.05;
**
p < 0.01.

increase in the remaining variables there was an increase in inten
tion by a factor of 1.14 (95% CI: 1.03–1.25, p = 0.010) for SES; 1.58 (95%
CI: 1.08–2.28, p = 0.017) for self-efficacy; and 1.73 (95% CI: 1.17–2.55,
p = 0.006) for negative attitudes toward uncertainty.
The analysis among the relatives cohort revealed that not having
a personal cancer diagnosis and reporting greater satisfaction with
the decision to have germline GS, were associated with greater in
tentions to change behavior. Relatives lacking a personal cancer di
agnosis were more likely (2.39 times; 95% CI: 1.16–4.95) to have
greater intentions to change their behavior compared to those who
had faced their own cancer diagnosis. For each category increase in
relatives’ satisfaction with their decision to have germline GS, the
ordered odds of having greater intention to change behavior in
creased by 3.33-fold (95% CI: 1.60–6.92, p = 0.001).
Posthoc univariate analyses explored whether particular knowl
edge items were more strongly associated with behavioral inten
tions. Knowing that GS is helpful for making decisions about future
cancer risks (p < 0.05, Dunn’s multiple comparisons test) and that
the likelihood of finding a gene variant to guide prevention depends
on the type of cancer (p < 0.05, Dunn’s multiple comparisons test)
were associated with greater intentions to change behavior.

earlier age at cancer onset, or the presence of multiple primary
cancers, rather than family history. Specifically, we assessed parti
cipants’ knowledge of germline GS and intention to change behavior
if they were to receive a pathogenic variant finding linked to
cancer risk.
4.2. Knowledge
Overall, participants’ knowledge of germline GS was moderate,
with participants scoring on average less than 50% on the studydesigned knowledge scale. Many participants over-estimated the
likelihood of obtaining an actionable result, and the utility of GS in
cancer. Unrealistic expectations of GS, which can result in dis
appointment, anxiety and decisional regret when these are not
realized [7], are common among patients undergoing GS in both
research and diagnostic settings [38–41]. In one study, many parti
cipants believed results would give them an absolute answer on
whether or not they would develop a specific disease. Unrealistic
expectations arise from the complexity and uncertainty inherent in
genomic results [42]. Several authors have suggested strategies at
both consent and return of results, to ensure patient expectations
are more accurate. These include repeating information, providing
written, personalized information and checking understanding [42].
Higher GS knowledge was predicted by higher levels of education
in both groups. These results are in accord with previous studies
correlating education and GS knowledge, albeit in different patient
populations and using different knowledge scales [8,11,13,32]. We
found probands’ previous attendance at an FCC was also predictive
of GS knowledge, consistent with findings of Rini and colleagues [8].

4. Discussion and conclusion
4.1. Discussion
Our study reports on a cancer-affected (personal or familial)
population who consented to germline GS as part of a larger research
study investigating heritable cancer risk, identified by virtue of
7
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Table 3
Summary of regression analyses for variables predicting behavioral intentions.
Independent variables

Sex
Female (Ref. category: Male)
Age (for every 10 year increase)
Education
Medical/science occupation
Yes (Ref. category: No)
English-speaking background
Yes (Ref. category: No)
Socio-economic status
Accessibility and Remoteness Index of Australia
Urban (Ref. category: Remote)
Family cancer clinic
Yes (Ref. category: No)
Married
Yes (Ref. category: No)
Biological children
Yes (Ref. category: No)
Family history of cancer
Yes (Ref. category: No)
Cancer diagnosis
No (Ref. category: Yes)
Multiple primary cancers
Yes (Ref. category: No)
Time since diagnosis
Cancer incidence
Common
Less common
Rare
Perceived importance
Satisfaction with decision
Self-efficacy
Perceived susceptibility (10 units scaled)
Attitude toward uncertainty
Knowledge

Probands

Relatives

Regression coefficient (95% CI)

p value

Regression coefficient (95% CI)

p value

1.93 (1.16–3.19)
0.89 (0.68–1.17)
0.88 (0.74–2.30)

0.011*
0.429
0.181

2.29 (1.19–4.38)
1.25 (0.98–1.86)
1.04 (0.86–1.26)

0.013*
0.266
0.683

0.53 (0.24–1.18)

0.119

1.17 (0.38–3.62)

0.789

**

2.51 (0.98–1.12)
1.14 (1.03–1.25)

0.003
0.010**

0.81 (0.29–2.28)
1.04 (0.92–1.17)

0.691
0.524

0.42 (0.13–1.30)

0.133

0.80 (0.26–2.42)

0.688

0.90 (0.53–1.53)

0.705

0.76 (0.29–2.02)

0.581

1.17 (0.69–2.20)

0.559

1.27 (0.62–2.60)

0.517

1.15 (0.63–2.13)

0.649

1.58 (0.80–3.14)

0.188
2.39 (1.16–4.95)

0.018*

3.71 (2.00–6.89)
3.33 (1.60–6.92)
0.91 (0.53–1.54)
0.92 (0.76–1.11)
1.58 (0.94–2.65)
0.57 (0.16–2.07)

<0.001***
0.001***
0.723
0.382
0.085
0.391

1.64 (0.80–3.35)
0.97 (0.94–1.00)

0.173
0.052

1.19 (0.70–2.02)
1.06 (0.44–2.51)
Ref.
3.80 (2.43–5.94)
1.28 (0.72–2.30)
1.58 (1.08–2.29)
0.92 (0.81–1.05)
1.73 (1.17–2.55)
0.70 (0.26–1.92)

0.530
0.903
<0.001***
0.398
0.017*
0.239
0.006**
0.490

Ref. = reference
*
p < 0.05;
**
p ≤ 0.01;
***
p ≤ 0.001.

This association may reflect the efficacy of education within FCCs, or
that those with higher knowledge are more likely to attend an FCC.
However, the feasibility of all research study participants attending
FCCs to become more educated about GS and its potential results/
implications is low due to limited resources at these centers. This
suggests that research and oncology staff will need upskilling to
provide more effective education, if participant knowledge is to
improve. Previous attendance at an FCC was not predictive of GS
knowledge for relatives. Perhaps relatives feel their family role is to
support the adult proband as opposed to learning about GS during
FCC visits.
Our expectation that higher GS knowledge would be associated
with demographics including higher SES, living in an urban area and
speaking English at home was not supported. This could be due to
the majority of the cohort living in an urban area with a high SES,
and perhaps, language is not a barrier to learning about GS.
Furthermore, having a family history of cancer, a more recent cancer
diagnosis or a rare cancer type was also not associated with GS
knowledge. These potential correlates were included as it was
thought they would precipitate discussions about cancer within the
family and encourage information-seeking about the potential utility
of GS (for heritable or treatment information). Additionally, asso
ciations between perceived cancer susceptibility and importance of
GS, attitude toward uncertainty and satisfaction with decision and
GS knowledge were not supported, perhaps due to a lack of variation
in these variables, with most participants reporting high suscept
ibility, high perceived importance of GS, negative attitude toward
uncertainty and high satisfaction with the decision to have GS.

Fig. 4. Baseline knowledge score and highest level of education. Knowledge scores of
those having completed secondary school (years 7–12) versus attended post-sec
ondary school (vocational training or university). Data indicate mean ± standard error
of the mean. P values calculated using an unpaired t-test.
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Agree

Neither agree or disagree

Strongly disagree

complex transnational ties and obligations that leave little room for
personal health as a priority [55]. Learning the reasons why these
subgroups are less likely to intend behavioral change is vital to
realizing equitable benefits of GS. Furthermore, increasing knowl
edge may help these vulnerable groups, but our results suggest this
is not sufficient, and other interventions to overcome disadvantage
may be needed.
Proposed predictors of intention to change behavior that were
not supported by the current study include education level, a
medical or science occupation and living in an urban environment.
These results are encouraging, as they suggest that where one lives
and one’s level of education do not need to be barriers to improving
lifestyle behaviors such as diet, exercise, alcohol consumption and
stress reduction. Furthermore, previously attending an FCC, having a
family history of cancer, more recent diagnosis of cancer, and a rare
cancer type were not associated with intention to change behavior.
These results indicate that personal, lived experience with any
cancer diagnosis may impact intention to change behavior more
than the more specific cancer-associated factors assessed.
In line with the PMT proposition that perceived efficacy of a
preventive behavior and higher self-efficacy to undertake that be
havior will lead to greater intention to change, perceived importance
of GS and higher self-efficacy were found to be predictive of pro
bands’, but not relatives’, intention to change behavior. Probands,
unlike relatives (most of whom did not have cancer), may have al
ready tried to make behavior changes to impact their cancer out
comes, so thus have learned about their own self-efficacy in making
these changes. Furthermore, analyzing probands’ intention to
change behavior based on cancer types that are and are not poten
tially modifiable by lifestyle (e.g. colorectal vs pancreas) revealed no
differences.
The third element of PMT theory (perceived threat, assessed here
by perceived susceptibility to cancer) was surprisingly not found to
be associated with behavioral intention, perhaps due to the lack of
variability in participants’ responses (> 70% of participants scored
≥ 50 on perceived susceptibility) and thus warrants exploration in
future research. In their meta-analysis of studies testing PMT in
predicting health-related behavior, Milne and colleagues [56] found
the relationship between perceived susceptibility and behavioral
intention was small, with efficacy variables having a larger effect.
They posited that while feeling vulnerable may motivate behavior,
enacting the behavior may lessen/remove this sense of vulnerability,
thereby removing the effect.
Relatives’ (but not probands’) satisfaction with their decision to
have GS was highly predictive of intention to change behavior.
Relatives’ satisfaction may relate to being highly motivated to make
behavior changes on the basis of genetic results. Conversely, pro
bands may have already made behavior changes after their cancer
diagnosis; their satisfaction with the decision to have GS may relate
more to understanding the etiology of their cancer diagnosis than to
future risk and behavior to avert it.
Limitations of the current study include the cross-sectional analysis,
which means that associations cannot be assumed to be causative.
Some measures utilized were study-developed (in the absence of ex
isting, validated measures) or adapted from other scales to address the
specific study scenario, and may not have fully or reliably assessed
study variables. Reliability and validity of the knowledge scale were not
assessed, and the scale asked study participants to indicate the like
lihood of some outcomes, which required familiarity with percentages
as a measure of likelihood. In addition, the perceived importance of GS
measure had a Cronbach’s alpha of 0.58, indicating that it may lack
internal consistency. It is not entirely clear whether knowledge as
sessed was background knowledge or obtained during the consent
process. One of the seven items in the knowledge questionnaire was
covered in the information sheet (that whole genome sequencing

Missing

Seek more
information

Probands

Want more
health screening

Probands

Be more careful
with diet

Probands

Manage stress
better

Probands

Relatives

Relatives

Relatives

Relatives
Probands

Exercise more

Relatives
Probands

Change amount of
alcohol consumed

Relatives
0

25

50

75

100

Percent of cohort
Fig. 5. Intention to change behavior responses. Participants were asked whether they
would change the indicated behavior if they knew they had inherited gene variants
that increased cancer risk. N = 348 for probands and N = 213 for relatives, except
“Change amount of alcohol consumed”, which excludes participants that do not
regularly drink alcohol (N = 214 for probands and N = 141 for relatives).

It is also possible that our study-developed knowledge scale was
insufficiently sensitive to identify key issues of importance to cancer
patients undertaking GS. In the time since the current study design
in 2016, additional validated knowledge measures have been de
veloped including the University of North Carolina Genomic
Knowledge Scale (UNC-GKS) [43] and Knowledge of Genome Se
quencing (KOGS) scale [44]. These scales examine knowledge in the
domains of genes, sequencing and heritability. Future studies using
either the UNC-GKS or KOGS scales will provide additional in
formation as to knowledge gaps which education needs to target.
4.3. Change in behavior
The current study adds to an existing literature base regarding
intention to change behaviors based on germline GS results [45–47],
and is unique in that all participants had a personal or familial ex
perience of cancer, with the majority being rare and less common
cancers. The strong overall intention to change behavior we ob
served aligns with the expectation that participants with personal
experience of cancer (self or family) would be highly motivated to
perform risk-reducing behaviors [48]. Our finding that females were
twice as likely as males to intend to change behaviors based on GS
results is in keeping with previous studies where females were more
likely to engage in health-promoting behaviors, including sunscreen
use, eating a healthy diet and reducing alcohol consumption [49–51].
Being from an English-speaking household and higher SES were
also associated with greater behavioral change intentions for pro
bands. Previous reports indicate that being from a non-Englishspeaking household is associated with decreased screening for
cancers such as breast and bowel cancers [52], and there is lower
uptake of cervical cancer screening in areas of lower SES [53]. It has
been suggested that individuals from low SES feel less in control of
their environment [54], and therefore less autonomy to change be
havior. Another study found that immigrants are often living with
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involves testing 20,000 genes). However, we cannot be certain that
other issues did not come up during informal discussion during the
consent process.
Finally, future longitudinal analyses that incorporate actual be
havior change are needed to further explore and corroborate our
findings regarding hypothetical intentions. The well-established in
tention-behavioral gap demonstrates that despite firm intentions to
change behavior, this is often not realized [57]. However, as re
searchers and health professionals often wish to identify and refine
behavior change strategies early, when behavioral outcome data is
not yet available, intention to change is still a worthy outcome to
explore. Furthermore, a meta-analysis of 47 studies found that while
the intention-behavior gap is a real phenomenon, a medium-tolarge change in intention leads to a small-to-medium change in
behavior, providing some predictive power [58]. Various strategies
have been suggested to bridge this gap, including increasing selfefficacy, detailed planning, and controlling one’s behavior [59],
which may be explored in future studies.
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4.4. Conclusion
Our study is the first to examine both knowledge and behavioral
intentions in an Australian population affected by mostly rare and
less common cancers (either self or family) undergoing germline GS
to determine gene variants associated with cancer risk. Future stu
dies examining whether receiving a germline GS result that indicates
a gene variant linked to cancer risk actually changes an individual’s
behavior, are warranted. The current findings are the first step to
wards determining whether germline GS in a cancer risk population
is worth the expense to the individual and/or the healthcare system,
via behavioral change.
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4.5. Practice implications
Our finding that participants had only moderate GS knowledge
identifies a need for increased education regarding the benefits and
limitations of GS in order to align patient expectations with likely
outcomes. Such educational resources may include plain language
summaries taken home from consent appointments or web-based
learning [60] and need to be targeted and accessible to all groups,
including those from non-English speaking and low socio-economic
backgrounds. Furthermore, patient-specific support such as smart
phone apps and access to support personnel [61,62] to encourage,
facilitate and maintain behavior change intentions should be em
ployed in individuals identified with a gene variant linked to in
crease cancer risk.
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